Diligence memo · auto-generated · as of July 2, 2026
Intarcia Therapeutics, Inc
Intarcia Therapeutics, Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Intarcia Therapeutics, Inc operates in Biotechnology, based in Boston. ABOUT US – Intarcia Life Sciences
Sub-sector tags: pharma.
Capital & rounds (filed)filed
Intarcia Therapeutics, Inc has raised $1.2B in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $525M on 2016-09-02.
Most recent recorded round closed around 2019-02-26.
Valuation (modeled)modeled
Provath models Intarcia Therapeutics, Inc at approximately $8.4B (range $1.2B–$15.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.44× the median modeled value of Growth/Late Biotechnology companies in 2019–2021 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 7.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Sana Biotechnology, Inc., National Resilience, Inc., Neumora Therapeutics, Inc., Vaxxinity, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.